LCDX (Caliber Imaging & Diagnostics) ROE %: 0.00% (As of Mar. 2014)


What is Caliber Imaging & Diagnostics ROE %?

Caliber Imaging & Diagnostics LCDX ROE % is 0.00% as of Mar. 2014.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Caliber Imaging & Diagnostics's annualized net income for the quarter that ended in Mar. 2014 was $-7.29 Mil. Caliber Imaging & Diagnostics's average Total Stockholders Equity over the quarter that ended in Mar. 2014 was $-13.34 Mil. Therefore, Caliber Imaging & Diagnostics's annualized ROE % for the quarter that ended in Mar. 2014 was N/A%.

The historical rank and industry rank for Caliber Imaging & Diagnostics's ROE % or its related term are showing as below:

LCDX's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.42
* Ranked among companies with meaningful ROE % only.

Caliber Imaging & Diagnostics  (OTCPK:LCDX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2014 )
=Net Income/Total Stockholders Equity
=-7.292/-13.3375
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.292 / 3.432)*(3.432 / 2.3105)*(2.3105 / -13.3375)
=Net Margin %*Asset Turnover*Equity Multiplier
=-212.47 %*1.4854*N/A
=ROA %*Equity Multiplier
=-315.6 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2014 )
=Net Income/Total Stockholders Equity
=-7.292/-13.3375
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-7.292 / -7.292) * (-7.292 / -6.34) * (-6.34 / 3.432) * (3.432 / 2.3105) * (2.3105 / -13.3375)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1502 * -184.73 % * 1.4854 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2014) net income data. The Revenue data used here is four times the quarterly (Mar. 2014) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Caliber Imaging & Diagnostics ROE % Related Terms


Caliber Imaging & Diagnostics ROE % Historical Data

* Premium members only.

The historical data trend for Caliber Imaging & Diagnostics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliber Imaging & Diagnostics ROE % Chart

Caliber Imaging & Diagnostics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13
ROE %
0.00 0.00 0.00 0.00 0.00

Caliber Imaging & Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LCDX vs VICA, CRVW, RSLS: ROE % Comparison

For the Medical Devices subindustry, Caliber Imaging & Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliber Imaging & Diagnostics ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's ROE % distribution charts can be found below:

* The bar in red indicates where Caliber Imaging & Diagnostics's ROE % falls into.



Caliber Imaging & Diagnostics ROE % Calculation

Caliber Imaging & Diagnostics's annualized ROE % for the fiscal year that ended in Dec. 2013 is calculated as

ROE %=Net Income (A: Dec. 2013 )/( (Total Stockholders Equity (A: Dec. 2012 )+Total Stockholders Equity (A: Dec. 2013 ))/ count )
=-5.479/( (-7.707+-12.493)/ 2 )
=-5.479/-10.1
=N/A %

Caliber Imaging & Diagnostics's annualized ROE % for the quarter that ended in Mar. 2014 is calculated as

ROE %=Net Income (Q: Mar. 2014 )/( (Total Stockholders Equity (Q: Dec. 2013 )+Total Stockholders Equity (Q: Mar. 2014 ))/ count )
=-7.292/( (-12.493+-14.182)/ 2 )
=-7.292/-13.3375
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2014) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Caliber Imaging & Diagnostics (LCDX) has a ROE % of 0.00% as of Mar. 2014. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' ROE % too high?
Caliber Imaging & Diagnostics' current ROE % is 0.00%.
How does Caliber Imaging & Diagnostics' ROE % compare to VICA and CRVW?
Caliber Imaging & Diagnostics' ROE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Caliber Imaging & Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliber Imaging & Diagnostics's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current ROE % is 0.00% as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caliber Imaging & Diagnostics Business Description

Address 50 Methodist Hill Drive, Suite 1000, Rochester, NY, USA, 14623
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.